Cue Biopharma Statistics
Total Valuation
Cue Biopharma has a market cap or net worth of $58.84 million. The enterprise value is $38.51 million.
Important Dates
The last earnings date was Tuesday, August 12, 2025, after market close.
| Earnings Date | Aug 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Cue Biopharma has 76.85 million shares outstanding. The number of shares has increased by 52.88% in one year.
| Current Share Class | 76.85M |
| Shares Outstanding | 76.85M |
| Shares Change (YoY) | +52.88% |
| Shares Change (QoQ) | +28.56% |
| Owned by Insiders (%) | 0.35% |
| Owned by Institutions (%) | 24.03% |
| Float | 76.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.82 |
| Forward PS | 6.21 |
| PB Ratio | 3.22 |
| P/TBV Ratio | 3.24 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.65 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.60, with a Debt / Equity ratio of 0.42.
| Current Ratio | 1.60 |
| Quick Ratio | 1.48 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -77.10 |
Financial Efficiency
Return on equity (ROE) is -195.55% and return on invested capital (ROIC) is -84.10%.
| Return on Equity (ROE) | -195.55% |
| Return on Assets (ROA) | -59.43% |
| Return on Invested Capital (ROIC) | -84.10% |
| Return on Capital Employed (ROCE) | -184.02% |
| Revenue Per Employee | $202,098 |
| Profits Per Employee | -$948,659 |
| Employee Count | 41 |
| Asset Turnover | 0.20 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +34.57% in the last 52 weeks. The beta is 1.59, so Cue Biopharma's price volatility has been higher than the market average.
| Beta (5Y) | 1.59 |
| 52-Week Price Change | +34.57% |
| 50-Day Moving Average | 0.80 |
| 200-Day Moving Average | 0.94 |
| Relative Strength Index (RSI) | 42.85 |
| Average Volume (20 Days) | 115,477 |
Short Selling Information
The latest short interest is 898,157, so 1.17% of the outstanding shares have been sold short.
| Short Interest | 898,157 |
| Short Previous Month | 956,793 |
| Short % of Shares Out | 1.17% |
| Short % of Float | 1.17% |
| Short Ratio (days to cover) | 2.17 |
Income Statement
In the last 12 months, Cue Biopharma had revenue of $8.29 million and -$38.90 million in losses. Loss per share was -$0.53.
| Revenue | 8.29M |
| Gross Profit | -24.74M |
| Operating Income | -39.48M |
| Pretax Income | -49.97M |
| Net Income | -38.90M |
| EBITDA | -39.08M |
| EBIT | -39.48M |
| Loss Per Share | -$0.53 |
Full Income StatementBalance Sheet
The company has $27.96 million in cash and $7.63 million in debt, giving a net cash position of $20.33 million or $0.26 per share.
| Cash & Cash Equivalents | 27.96M |
| Total Debt | 7.63M |
| Net Cash | 20.33M |
| Net Cash Per Share | $0.26 |
| Equity (Book Value) | 18.16M |
| Book Value Per Share | 0.24 |
| Working Capital | 11.59M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$28.14 million and capital expenditures -$178,000, giving a free cash flow of -$28.32 million.
| Operating Cash Flow | -28.14M |
| Capital Expenditures | -178,000 |
| Free Cash Flow | -28.32M |
| FCF Per Share | -$0.37 |
Full Cash Flow StatementMargins
| Gross Margin | -298.54% |
| Operating Margin | -476.43% |
| Pretax Margin | -469.41% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Cue Biopharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -52.88% |
| Shareholder Yield | -52.88% |
| Earnings Yield | -66.10% |
| FCF Yield | -48.13% |
Analyst Forecast
The average price target for Cue Biopharma is $3.00, which is 291.80% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.00 |
| Price Target Difference | 291.80% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 75.28% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Cue Biopharma has an Altman Z-Score of -13.52 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -13.52 |
| Piotroski F-Score | 3 |
